Practical challenges with SGLT2i therapy in patients with T2DM and CKD
Click here to watch this as part of CME accredited course
Video navigation menu
- What should a physician explain to a patient at the start of SGLT2i therapy? 00:32
- What if a patients is already on hyperglycemic therapy? 02:25
- What about DKA and SGLT2i? 04:02
- Considerations around foot care 05:49
- Management of diurectics in patients taking SGLT2i 07:04
- eGFR at initiation of SGLT2i therapy 07:43
- Summary 10:59
What is true about SGLT2i therapy in relation to diabetic ketoacidosis (DKA)?
- A. SGLT2i can cause DKA
- B. SGLT2i increase the threshold to develop DKA
- C. SGLT2i can mask DKA or lower the threshold to develop DKA, but do not cause DKA
- D. SGLT2i should be continued during acute illness
- E. SGLT2i and insulin should be stopped during acute illness
This lecture by Alice Cheng was part of the EBAC-accredited symposium "SGLT2i in CKD: How to overcome clinical inertia?" held during the virtual ERA EDTA 2021 congress.
Alice Cheng, MD is an endocrinologist at Credit Valley Hospital, Mississauga, ON, Canada and Associate Professor at the University of Toronto, ON, Canada.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: